The absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use
Gregory P Kaufman,1 Kay M Ristow,1,2 Svetomir N Markovic,1,2 Luis F Porrata1,2 1Department of Internal Medicine, 2Division of Hematology, Mayo Clinic, Rochester, MN, USA Abstract: Risk stratification of patients with classical Hodgkin lymphoma (cHL) remains suboptimal. The ratio of the absolute ly...
Saved in:
Main Authors: | Kaufman GP, Ristow KM, Markovic SN, Porrata LF |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2014
|
Subjects: | |
Online Access: | https://doaj.org/article/7fd25cc8e5eb42a7bd9fa81a4f9a54ee |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
by: Lai C, et al.
Published: (2019) -
MEDICAL TREATMENT IN HODGKIN LYMPHOMA
by: Nilgun Kurucu
Published: (2021) -
ANTICARDIOLIPINIC ANTIBODIES IN NON-HODGKIN LYMPHOMA
by: Sanda Buruiana, et al.
Published: (2021) -
The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma
by: Eko A. Pangarsa, et al.
Published: (2021) -
MicroRNA dysregulation in B-cell non-Hodgkin lymphoma
by: Lim EL, et al.
Published: (2013)